Immunocore
A leading T cell receptor (TCR) biotechnology company working to create first-in-class biological therapies to address unmet patient needs in oncology as well as infectious and autoimmune diseases.
Launch date
Employees
Market cap
CAD2.3b
Enterprise valuation
CAD1.7b (Public information from Sep 2024)
Share price
$34.44 IMCR
Company register number 06456207
Milton England (HQ)
Financials
Estimates*
| GBP | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 30.1m | 26.5m | 144m | 249m | 240m | 268m | 288m |
| % growth | 17 % | (12 %) | 442 % | 74 % | (4 %) | 12 % | 7 % |
| EBITDA | (75.4m) | (135m) | (36.5m) | (38.5m) | (72.4m) | (110m) | (111m) |
| % EBITDA margin | (251 %) | (509 %) | (25 %) | (15 %) | (30 %) | (41 %) | (39 %) |
| Profit | (74.1m) | (132m) | (41.2m) | (55.3m) | (70.1m) | (83.1m) | (103m) |
| % profit margin | (246 %) | (496 %) | (29 %) | (22 %) | (29 %) | (31 %) | (36 %) |
| EV / revenue | - | 35.2x | 14.0x | 9.4x | 4.6x | 4.4x | 4.6x |
| EV / EBITDA | - | -6.9x | -55.0x | -60.8x | -15.2x | -10.9x | -11.9x |
| R&D budget | 74.8m | 73.2m | 89.2m | 164m | - | - | - |
| R&D % of revenue | 248 % | 276 % | 62 % | 66 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
N/A | Corporate spinout | ||
N/A | Grant | ||
£2.4m | Grant | ||
$320m Valuation: $950m -98.4x EV/LTM EBITDA | Series A | ||
* | $40.0m | Series B | |
$130m Valuation: $620m 18.3x EV/LTM Revenues -4.4x EV/LTM EBITDA | Series B | ||
$75.0m | Series C | ||
| N/A | $43.2m Valuation: $1.2b 29.7x EV/LTM Revenues -11.8x EV/LTM EBITDA | IPO | |
* | $140m | Private Placement VC | |
* | N/A | $300m | Post IPO Convertible |
| Total Funding | CAD966m | ||
Related Content
Recent News about Immunocore
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.